Parathyroidectomy versus cinacalcet for the correction of secondary hyperparathyroidism in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON29506

Enrollment

128

Registered

2015-08-25

Start date

2016-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The use of Cinacalcet in secondary hyperparathyroidism and chronic renal failure instead of Total parathyroidectomy

Interventions

Total parathyroidectomy with transplantation versus the use of Cinacalcet

Eligibility

Inclusion criteria

Inclusion criteria: - Age > 18 years - Newly diagnosed sHPT, defined as PTH level >9x ULN -Hemodialysis or peritoneal dialysis patients -> 3 months of chronic dialysis - Signed informed consent

Exclusion criteria

Exclusion criteria: -Cinacalcet use within the past 3 months -Former renal transplant -Former parathyroidectomy -Former dialysis -Malignancy in history

Design outcomes

Primary

Measure	Time frame
PTH 3 months after the intervention	—

Secondary

Measure	Time frame
- cardiovascular events (myocardial infarction, peripheral vascular disease, instable angina, cerebrovascular disease, CVA, TIA), arrhythmias) - Costs - phosphorus, calcium - fibroblast growth factor 23 levels - renal function - all-cause mortality	—

Contacts

Public ContactSchelto Kruijff

Hanzeplein 1a UMCG

s.kruijff@umcg.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)